Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hu14.18-IL2 in recurrent or refractory neuroblastoma
NCT00082758Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Aug 2005
- Primary completion
- Feb 2008
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of Lorukafusp alfa in neuroblastoma, sponsored by Children's Oncology Group. Started Aug 2005; status: completed.
02
Drugs
Lorukafusp alfa
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00082758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082758.